Northeast Pharmaceutical Group To Give Up Stake In ShenYang TCM Pharmaceutical
This article was originally published in PharmAsia News
The Shenyang Property Rights Transaction Center's information shows that Northeast Pharmaceutical Group plans to transfer its 20 percent stake in ShenYang TCM Pharmaceutical at a price of RMB 35 million ($5.1 million). ShenYang TCM Pharmaceutical, a Sino-British joint venture, is one of China's key TCM pharmaceutical companies. It mainly engages in Chinese patent medicine R&D, processing and manufacturing; TCM extraction; herbal medicine processing; as well as medicinal raw material purchasing. The firm's major product Shenyang Hongyao has become a renowned brand in the nation's TCM industry. A manager of the transaction reveals that Northeast Pharmaceutical Group's move stems from investment restructuring, which will focus the development of its core chemical medicine business. (Click here for more - Chinese Language)
You may also be interested in...
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.